ESMO News

Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer

noreply@esmo.org — Tue, 25 Aug 2026 07:08:00 +00:00

Findings from the ENZAMET (ANZUP 1304) study

Metastatic Breast Cancer: ESMO Living Guideline

noreply@esmo.org — Mon, 24 Aug 2026 13:08:00 +00:00

Prepared by E de Azambuja and N Harbeck, the ESMO Metastatic Breast Cancer Living Guideline provides immediate access to the latest recommendations from the June 2026 CPG, with notable systemic treatment updates across several breast cancer subtypes, delivered through an interactive, mobile-friendly format

No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation

noreply@esmo.org — Mon, 24 Aug 2026 07:08:00 +00:00

Findings from the SKYSCRAPER-03 study

EMA Recommends Extension of Indications for Datopotamab Deruxtecan

noreply@esmo.org — Fri, 21 Aug 2026 07:08:00 +00:00

New indication concerns the first-line treatment of adult patients with unresectable or metastatic TNBC, who are not candidates for PD-(L)1 inhibitor therapy

High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma

noreply@esmo.org — Thu, 20 Aug 2026 07:08:00 +00:00

Findings from the MATRix/IELSG43 study

ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer

noreply@esmo.org — Wed, 19 Aug 2026 08:08:00 +00:00

Updated recommendations include daraxonrasib for second-line treatment of metastatic pancreatic cancer. This oral multi-selective RAS(ON) inhibitor has demonstrated significant improvements in overall survival and quality of life outcomes.

FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications

noreply@esmo.org — Wed, 19 Aug 2026 06:08:00 +00:00

Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies

Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors

noreply@esmo.org — Tue, 18 Aug 2026 08:08:00 +00:00

Findings from the LITESPARK-011 study

Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer

noreply@esmo.org — Mon, 17 Aug 2026 08:08:00 +00:00

Findings from the PSMAddition study

EMA Recommends Extension of Therapeutic Indications for Cetuximab

noreply@esmo.org — Fri, 14 Aug 2026 07:08:00 +00:00

New indications concern the treatment of adult patients with BRAF V600E-mutated mCRC in combination with encorafenib

No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Thu, 13 Aug 2026 07:08:00 +00:00

Findings from the ENDURANCE study

FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies

noreply@esmo.org — Wed, 12 Aug 2026 07:08:00 +00:00

Evidence for efficacy is based on the results from the Precision-T study

Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC

noreply@esmo.org — Tue, 11 Aug 2026 07:08:00 +00:00

Findings from the COMMIT study

Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism

noreply@esmo.org — Mon, 10 Aug 2026 07:08:00 +00:00

Findings from the Hydra study

EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength

noreply@esmo.org — Fri, 07 Aug 2026 07:08:00 +00:00

New indication concerns a monotherapy in paediatric patients with CP-CML who are resistant or intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or who have the T315I mutation

Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL

noreply@esmo.org — Thu, 06 Aug 2026 07:08:00 +00:00

Findings from the BRUIN CLL-322 study

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC

noreply@esmo.org — Wed, 05 Aug 2026 07:08:00 +00:00

Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies

Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels

noreply@esmo.org — Tue, 04 Aug 2026 07:08:00 +00:00

Findings from the RxPONDER study

Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response

noreply@esmo.org — Mon, 03 Aug 2026 07:08:00 +00:00

Findings from the Neo-CheckRay study

EMA Recommends Extension of Therapeutic Indications for Serplulimab

noreply@esmo.org — Fri, 31 Jul 2026 07:07:00 +00:00

New indication concerns a combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with unresectable, locally advanced or metastatic squamous NSCLC